The findings suggest that targeting KRAS expression, particularly through G4 ligands, holds potential for modulating tumor immunity, but further exploration into the specific mechanisms by which these ligands could influence the immune responses associated with KRAS mutations is needed. The gene discussed is KRAS; the disease is neoplasm.